# US 2022/0025050 A1 · Bifunctional molecule directed against human pd-1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0025050 A1
- Document ID: US20220025050A1
- Status: Published application
- Kind: A1
- Application number: 17/414,968
- Filed: 2019-12-17
- Published: 2022-01-27
- Earliest claimed: 2018-12-21
- Assignees: Ose Immunotherapeutics
- Applicants: Ose Immunotherapeutics
- Inventors: NICOLAS POIRIER; CAROLINE MARY; VIRGINIE THEPENIER; AURORE MORELLO
- Web page: https://patentgrep.com/patent/US20220025050A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/54: Interleukins [IL]
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C12N 2510/00: Genetically modified cells
- C12N 2800/00: Nucleic acids vectors
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a bifunctional molecule comprising a humanized anti-hPD-1 antibody or antigen binding fragment thereof linked to an immunotherapeutic agent able to specifically enhance the immune response and uses thereof.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A bifunctional molecule consisting of:
(a) a humanized anti-human PD-1 antibody or antigen-binding fragment thereof, which comprises:
(i) a heavy chain variable domain (VH) comprising HCDR1, HCDR2 and HCDR3, and
(ii) a light chain variable domain (VL) comprising LCDR1, LCDR2 and LCDR3,
wherein:
the heavy chain CDR1 (HCDR1) comprises or consists of an amino acid sequence of SEQ ID NO: 1;
the heavy chain CDR2 (HCDR2) comprises or consists of an amino acid sequence of SEQ ID NO: 2;
the heavy chain CDR3 (HCDR3) comprises or consists of an amino acid sequence of SEQ ID NO: 3 wherein X1 is D or E and X2 is selected from the group consisting of T, H, A, Y, N, E and S;
the light chain CDR1 (LCDR1) comprises or consists of an amino acid sequence of SEQ ID NO: 12 wherein X is G or T;
the light chain CDR2 (LCDR2) comprises or consists of an amino acid sequence of SEQ ID NO: 15,
the light chain CDR3 (LCDR3) comprises or consists of an amino acid sequence of SEQ ID NO:16,
and
(b) an immunotherapeutic agent or a fragment thereof,
wherein the C-terminal end of the heavy and/or light chain(s) of the antibody or antigen-binding fragment thereof is covalently linked to the N-terminal end of the immunotherapeutic agent as a fusion protein, optionally by a peptide linker.

### Claim 26 (depends on 25)

The bifunctional molecule of claim 25, wherein the humanized anti-human PD-1 antibody or antigen-binding fragment thereof, comprises (a) a VH comprising or consisting of an amino acid sequence of SEQ ID NO: 17, wherein X1 is D or E and X2 is selected from the group consisting of T, H, A, Y, N, E and S; and (b) a VL comprising or consisting of an amino acid sequence of SEQ ID NO: 26, wherein X is G or T.

### Claim 27 (depends on 25)

The bifunctional molecule of claim 25, wherein the antibody or antigen binding fragment thereof is an antagonist of the binding of human PDL-1 and/or PD-L2 to human PD1.

### Claim 28 (depends on 25)

The bifunctional molecule of claim 25, wherein the immunotherapeutic agent or fragment thereof is selected from the group consisting of tumor targeting peptides, cytokines, cytokines receptors, chemokines, chemokines receptors, costimulatory molecules, inhibitory or coinhibitory molecules, molecular chaperone inhibitors, and human transmembrane immune protein of type I or II.

### Claim 29 (depends on 25)

The bifunctional molecule of claim 25, wherein the immunotherapeutic agent fragment thereof has a size comprised between 10 kDa and 50 kDa.

### Claim 30 (depends on 28)

The bifunctional molecule of claim 28, wherein the immunotherapeutic agent is a human transmembrane immune protein of type I or a fragment thereof selected from the group consisting of ICOSL, CD86, B7H4, B7H3, CD28H, PDL2, PDL1, DNAM, CTLA-4, Lag-3, TIGIT, 2B4, BTLA, HVEM, CD101, nectin-1, nectin-2, nectin-3, NELC-5, TLT-2, LFA-3, TIM3, TIM4, LAIR1, SIRPG, IL10R, IL6RA, IL-1R1, IL-1RAcP, IL6RB, TGFBRII, CSF1R, IL22R, VEGFR1, VEGFR2, VEGFR3, CD111, CD112, CD155, CD113, VISTA, CD244, OX40, SIRPalpha, CD80, CD24, Siglec-10, Fas, IL15RA, SIRB1, SIRB2, LTBR, IL21R and GITR.

### Claim 31 (depends on 28)

The bifunctional molecule of claim 28, wherein the immunotherapeutic agent is a human transmembrane immune protein of type II or a fragment thereof selected from the group consisting of CD40L, OX40L, FasL, TRAIL, TNF, LIGHT, APRIL, GITRL, CD30, CD70, CD40, CD27, CD30, CD153, RANK, CD96, CLEC1, CLEC2/CLE1B, CLEC3A, CLEC4A, CLEC4E, CLEC4L, CLEC51, CLEC6, CLEC7A, NKG2D, BTL-II, TGFRII, DECTIN-1, DC-SIGN, LT-alpha, LT-beta, 4-1BBL and MINCLE.

### Claim 32 (depends on 28)

The bifunctional molecule of claim 28, wherein the immunotherapeutic agent is a cytokine or a fragment thereof selected from the group consisting of TGFβ, IL-1, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12A, IL12B, IL-15, IL-21 and IL-18.

### Claim 33 (depends on 28)

The bifunctional molecule of claim 28, wherein the immunotherapeutic agent is a human IL-2 or a mutant thereof.

### Claim 34 (depends on 25)

The bifunctional molecule of claim 25, wherein the antibody or antigen-binding fragment thereof comprises a light chain constant domain derived from a human kappa light chain constant domain and a heavy chain constant domain derived from a human IgG1, IgG2, IgG3 or IgG4 heavy chain constant domain.

### Claim 35 (depends on 25)

The bifunctional molecule of claim 25, wherein the antibody or antigen-binding fragment thereof comprises a light chain constant domain derived from a human kappa light chain constant domain and a heavy chain constant domain derived from a human IgG1 heavy chain constant domain, optionally with a substitution or a combination of substitutions selected from the group consisting of T250Q/M428L; M252Y/S254T/T256E+H433K/N434F; E233P/L234V/L235A/G236A+A327G/A330S/P331S; E333A; S239D/A330L/I332E; P257I/Q311; K326W/E333S; S239D/I332E/G236A; N297A; L234A/L235A; N297A+M252Y/S254T/T256E; K322A; and K444A.

### Claim 36 (depends on 25)

The bifunctional molecule of claim 25, wherein the antibody or antigen-binding fragment thereof comprises a light chain constant domain derived from a human kappa light chain constant domain and a heavy chain constant domain derived from a human IgG4 heavy chain constant domain, optionally with a substitution or a combination of substitutions selected from the group consisting of S228P, L234A/L235A, S228P+M252Y/S254T/T256E and K444A.

### Claim 37 (depends on 25)

An isolated nucleic acid sequence or a group of isolated nucleic acid molecules encoding the bifunctional molecule of claim 25.

### Claim 38 (depends on 37)

A vector comprising the nucleic acid or group of nucleic acid molecules of claim 37.

### Claim 39 (depends on 37)

A host cell comprising the nucleic acid or group of nucleic acid molecules of claim 37 or a vector comprising said nucleic acid or group of nucleic acids.

### Claim 40 (depends on 39)

A method for producing the bifunctional molecule comprising a step of culturing a host cell of claim 39 and optionally a step of isolating the bifunctional molecule.

### Claim 41 (depends on 25)

A pharmaceutical composition comprising the bifunctional molecule of claim 25 and a pharmaceutically acceptable carrier.

### Claim 42 (depends on 41)

The pharmaceutical composition of claim 41, wherein the pharmaceutical composition further comprises an additional therapeutic agent selected from the group consisting of alkylating agents, angiogenesis inhibitors, antibodies, antimetabolites, antimitotics, antiproliferatives, antivirals, aurora kinase inhibitors, apoptosis promoters, activators of death receptor pathway, Bcr-Abl kinase inhibitors, BiTE (Bi-Specific T cell Engager) antibodies, antibody drug conjugates, biologic response modifiers, Bruton's tyrosine kinase (BTK) inhibitors, cyclin-dependent kinase inhibitors, cell cycle inhibitors, cyclooxygenase-2 inhibitors, DVDs, leukemia viral oncogene homolog (ErbB2) receptor inhibitors, growth factor inhibitors, heat shock protein (HSP)-90 inhibitors, histone deacetylase (HDAC) inhibitors, hormonal therapies, immunologicals, inhibitors of apoptosis proteins (IAPs), intercalating antibiotics, kinase inhibitors, kinesin inhibitors, Jak2 inhibitors, mammalian target of rapamycin inhibitors, microRNAs, mitogen-activated extracellular signal-regulated kinase inhibitors, multivalent binding proteins, non-steroidal anti-inflammatory drugs (NSAIDs), poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitors, platinum chemotherapeutics, polo-like kinase (Plk) inhibitors, phosphoinositide-3 kinase (PI3K) inhibitors, proteasome inhibitors, purine analogs, pyrimidine analogs, receptor tyrosine kinase inhibitors, retinoids/deltoids plant alkaloids, small inhibitory ribonucleic acids (siRNAs), topoisomerase inhibitors, ubiquitin ligase inhibitors, hypomethylating agents, checkpoints inhibitors, peptide vaccine, epitopes or neoepitopes from tumor antigens, and combinations of one or more of these agents.

### Claim 43 (depends on 41)

A method of treating cancer comprising the administration of a pharmaceutical composition of claim 41 to a subject in need of treatment.

### Claim 44 (depends on 43)

The method of claim 43, wherein the cancer is selected from the group consisting of a hematologic malignancy or a solid tumor with expression of PD-1 and/or PD-L1, hematolymphoid neoplasms, angioimmunoblastic T cell lymphoma, myelodysplastic syndrome, and acute myeloid leukemia, a cancer induced by virus or associated with immunodeficiency, Kaposi sarcoma, cervical, anal, penile and vulvar squamous cell cancer and oropharyngeal cancers. B cell non-Hodgkin lymphomas (NHL), diffuse large B-cell lymphoma, Burkitt lymphoma, plasmablastic lymphoma, primary central nervous system lymphoma, HHV-8 primary effusion lymphoma, classic Hodgkin lymphoma, and lymphoproliferative disorders, hepatocellular carcinoma, Merkel cell carcinoma, cancer associated with human immunodeficiency virus infection (HIV) infection, a metastatic or nonmetastatic cancer, Melanoma, malignant mesothelioma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Hodgkin's Lymphoma, Head and Neck Cancer, Urothelial Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Metastatic Merkel Cell Carcinoma, Gastric or Gastroesophageal cancers and Cervical Cancer.

### Claim 45 (depends on 43)

The method of claim 43, said method comprising the administration of said composition in combination with radiotherapy or an additional therapeutic agent selected from the group consisting of alkylating agents, angiogenesis inhibitors, antibodies, antimetabolites, antimitotics, antiproliferatives, antivirals, aurora kinase inhibitors, apoptosis promoters, activators of death receptor pathway, Bcr-Abl kinase inhibitors, BiTE (Bi-Specific T cell Engager) antibodies, antibody drug conjugates, biologic response modifiers, Bruton's tyrosine kinase (BTK) inhibitors, cyclin-dependent kinase inhibitors, cell cycle inhibitors, cyclooxygenase-2 inhibitors, DVDs, leukemia viral oncogene homolog (ErbB2) receptor inhibitors, growth factor inhibitors, heat shock protein (HSP)-90 inhibitors, histone deacetylase (HDAC) inhibitors, hormonal therapies, immunologicals, inhibitors of apoptosis proteins (IAPs), intercalating antibiotics, kinase inhibitors, kinesin inhibitors, Jak2 inhibitors, mammalian target of rapamycin inhibitors, microRNAs, mitogen-activated extracellular signal-regulated kinase inhibitors, multivalent binding proteins, non-steroidal anti-inflammatory drugs (NSAIDs), poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitors, platinum chemotherapeutics, polo-like kinase (Plk) inhibitors, phosphoinositide-3 kinase (PI3K) inhibitors, proteasome inhibitors, purine analogs, pyrimidine analogs, receptor tyrosine kinase inhibitors, retinoids/deltoids plant alkaloids, small inhibitory ribonucleic acids (siRNAs), topoisomerase inhibitors, ubiquitin ligase inhibitors, hypomethylating agents, checkpoints inhibitors, peptide vaccine, epitopes or neoepitopes from tumor antigens, and combinations of one or more of these agents.

### Claim 46 (depends on 41)

A method of treating infectious disease, chronic infectious disease, or chronic viral infections comprising the administration of a composition of claim 41 to a subject in need of treatment.

### Claim 47 (depends on 46)

The method of claim 46, wherein the infectious disease is caused by a virus selected from the group consisting of HIV, hepatitis virus, herpes virus, adenovirus, influenza virus, flaviviruses, echovirus, rhinovirus, coxsackie virus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus.
